Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis
Endocrinology, Diabetes & Metabolism · 2025
DOI: 10.1002/edm2.70067 ↗At a glance
Systematische Übersicht in Endocrinology, Diabetes & Metabolism, 2025. Written by Saaed Abunada and 13 co-authors. Institution: Liaquat University of Medical and Health Sciences, Jamshoro, Karachi, Pakistan. Major MEDLINE topics: Insulin, Long-Acting, Hypoglycemia, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Cited 4 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control. However, comprehensive comparisons with insulin degludec regarding continuous glucose monitoring (CGM) metrics and hypoglycaemia outcomes remain limited. This meta‐analysis evaluates these critical parameters.
Methods
We conducted a systematic review and meta‐analysis of randomised controlled trials (RCTs) comparing once‐weekly BIF with once‐daily insulin degludec in type 1 and type 2 diabetes. Outcomes included CGM‐derived glycaemic variability, time in range, time above/below range and hypoglycaemia event rates. Data were pooled using random‐effects models, with heterogeneity assessed via I 2 statistics.
Results
Five RCTs ( n = 2427) were included. BIF demonstrated comparable glycaemic variability (within‐day CV: MD = 0.06, p = 0.90; between‐day CV: MD = ‐0.26, p = 0.30) and Time in range (MD = 0.56, p = 0.27) versus degludec. However, BIF increased time spent in the mild hypoglycaemia range (54–69 mg/dL) (MD = 0.30, p = 0.0004) and clinically significant hypoglycaemia event rates (rate ratio = 1.20, p < 0.00001). Severe hypoglycaemia event rates were higher with BIF (rate ratio = 3.34, p < 0.0001). Nocturnal hypoglycaemia and time above range (> 250 mg/dL) did not differ significantly.
Conclusion
Once‐weekly BIF provides similar overall glycaemic control to insulin degludec but with increased time in mild hypoglycaemia and higher event rates of clinically significant and severe hypoglycaemia. These findings highlight the need for individualised dosing and monitoring when transitioning to weekly insulin regimens.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Liaquat University of Medical and Health Sciences, Jamshoro, Karachi, Pakistan.
- United Medical and Dental College, Karachi, Pakistan.
- Carroll High School, Southlake, Texas, USA.
- Khairpur Medical College, Khairpur, Pakistan.
- Al-Tibri Medical College, Karachi, Pakistan.
- Liaquat National Hospital and Medical College, Karachi, Pakistan.
ORCID profiles: Salih Abdella Yusuf
Cite
APA
Abunada, S., Bai, S., Kumari, U., Nancy, F. N. U., Khan, A., Bai, N., Shevani, F. N. U., Bai, A., Dev, S., Zain Ul Abiddin, N., Umer, F. N. U., Manan, A., Bhutto, S. H., & Yusuf, S. A. (2025). Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70067
Vancouver
Abunada S, Bai S, Kumari U, Nancy FNU, Khan A, Bai N, et al. Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70067
BibTeX
@article{Abunada2025,
author = {Abunada, Saaed and Bai, Sheela and Kumari, Usha and Nancy, F N U and Khan, Areeba and Bai, Nikeeta and Shevani, F N U and Bai, Anusha and Dev, Shah and Zain Ul Abiddin, Noshad and Umer, F N U and Manan, Abdul and Bhutto, Sadia Habib and Yusuf, Salih Abdella},
title = {Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
doi = {10.1002/edm2.70067}
}
EUVIMED